Vincenzo Montesarchio
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial(2018)1,309 cited
- → Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis(2009)205 cited
- → Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study(2016)134 cited
- → Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial(2014)116 cited
- → Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey(2020)109 cited
- → Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX(2016)98 cited
- → The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response(2020)93 cited
- → Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy(2020)89 cited
- → Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study(2009)78 cited
- → Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study(2008)75 cited